Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral UTD2 in advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
CTR20252556Phase 2Active
- Sponsor
- 成都华昊中天药业有限公司/ 北京华昊中天生物医药股份有限公司
- Start
- Sep 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by 成都华昊中天药业有限公司/ 北京华昊中天生物医药股份有限公司. Started Sep 2025; status: active.
02
Drugs
utidelone
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20252556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252556.